摘要
目的探讨福辛普利联合阿魏酸钠注射液治疗糖尿病肾脏病(DKD)患者的临床疗效和安全性。方法 120例糖尿病肾脏病住院患者随机分为治疗组60例和对照组60例,两组均给予常规的糖尿病治疗。治疗组给予福辛普利联合阿魏酸钠注射液,对照组仅给予福辛普利。4周后观察治疗前后症状、体征变化,测定尿蛋白排泄率(UAER)、空腹血糖(FBG)、血尿素氮(BUN)、肌酐(Scr)、胆固醇(TC)、甘油三酯(TG)、血钾(K+)及药物不良反应。结果治疗前后两组UAER、FBG、TG和TC降低明显(P<0.05),而且治疗组更优于对照组(P<0.05);两组治疗前后K+、BUN和Scr比较,差异无统计学意义。结论福辛普利联合阿魏酸钠注射液治疗糖尿病肾脏病,能显著降低尿蛋白排泄率,减轻了肾脏损害,优于单纯福辛普利组,但未见明显不良反应增加,具有较好的临床疗效和安全性。
Objective To investigate the efficacy and safety of fosinopril with sodium ferulate injection therapy in diabetic kidney disease. Methods 120 diabetic kidney disease patients were randomized into two groups ： the treatment group（n=60）and the control group（n=60）.The two groups were both routinely treated with general treatment for diabetic,the treatment group was treated by fosinopril united sodium ferulate injection,and the control group was only treated by fosinopril.after 4 weeks of treatment to observe the change of symptoms of the two groups and test urinous protein excretion（UAER）,FBG,BUN,Scr,K＋,TG and TC,the dafta obtained from two groups were compared with each other and analysed statistically. Results Compared with pretreatment,at the end of 4 weeks′ treatment,the level of UAER was significantly lower,TG and TC levels decreased after therapy than before therapy in both groups（P0.05）,and the treatment group had an better effect than the control group（P0.05）.The changes of FBG,BUN,Scr and K＋ were similar between the two groups（P0.05）. Conclusion Fosinopril united sodium ferulate injection has obvious efficacy and safety for the treatment of diabetic kidney disease patients than the only fosinopril.
出处
《河南科技大学学报（医学版）》
2012年第1期37-39,共3页
Journal of Henan University of Science & Technology:Medical Science
关键词
糖尿病肾脏病
福辛普利
阿魏酸钠
尿蛋白排泄率
diabetic kidney disease
fosinopril
sodium ferulate
urinous protein excretion
